Bioluminescence imaging of myeloperoxidase activity in vivo

The myeloperoxidase (MPO) system of activated phagocytes is central to normal host defense mechanisms, and dysregulated MPO contributes to the pathogenesis of inflammatory disease states ranging from atherosclerosis to cancer. Here we show that upon systemic administration, the small molecule luminol enables noninvasive bioluminescence imaging (BLI) of MPO activity in vivo. Luminol-BLI allowed quantitative longitudinal monitoring of MPO activity in animal models of acute dermatitis, mixed allergic contact hypersensitivity, focal arthritis and spontaneous large granular lymphocytic tumors. Bioluminescence colocalized with histological sites of inflammation and was totally abolished in gene-deleted Mpo−/− mice, despite massive tissue infiltration of neutrophils and activated eosinophils, indicating that eosinophil peroxidase did not contribute to luminol-BLI in vivo. Thus, luminol-BLI provides a noninvasive, specific and highly sensitive optical readout of phagocyte-mediated MPO activity in vivo and may enable new diagnostic applications in a wide range of acute and chronic inflammatory conditions.

[1]  John W. Chen,et al.  A paramagnetic contrast agent with myeloperoxidase-sensing properties. , 2006, Organic & biomolecular chemistry.

[2]  K. Van Dyke,et al.  In vitro evaluation of opsonic and cellular granulocyte function by luminol-dependent chemiluminescence: utility in patients with severe neutropenia and cellular deficiency states , 1978, Infection and immunity.

[3]  M. Lindsay,et al.  Pharmacology of the eosinophil. , 1999, Pharmacological reviews.

[4]  S. Irie.  The treatment of alopecia areata with 3-aminophthal-hydrazide. , 1960, Current therapeutic research, clinical and experimental.

[5]  E. P. Brestel.  Co-oxidation of luminol by hypochlorite and hydrogen peroxide implications for neutrophil chemiluminescence. , 1985, Biochemical and biophysical research communications.

[6]  D. Piwnica-Worms,et al.  Monitoring proteasome activity in cellulo and in living animals by bioluminescent imaging: technical considerations for design and use of genetically encoded reporters. , 2005, Methods in enzymology.

[7]  Ralph Weissleder,et al.  Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. , 2006, Radiology.

[8]  Chunxiang Zhang,et al.  Myeloperoxidase, a Leukocyte-Derived Vascular NO Oxidase , 2002, Science.

[9]  S. Pennathur,et al.  Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.

[10]  John Saunders,et al.  Friend and Foe , 1890, The Hospital.

[11]  E. Masliah,et al.  Myeloperoxidase Polymorphism Is Associated with Gender Specific Risk for Alzheimer's Disease , 1999, Experimental Neurology.

[12]  D. Piwnica-Worms,et al.  Real-time bioluminescence imaging of myeloperoxidase activity in small laboratory animals , 2009 .

[13]  J. Heinecke.  Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. , 1999, The Journal of laboratory and clinical medicine.

[14]  E. Malle,et al.  Myeloperoxidase in kidney disease. , 2003, Kidney international.

[15]  C. Heeschen,et al.  Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.

[16]  H. Koyama,et al.  Earlier onset of neutrophil-mediated inflammation in the ultraviolet-exposed skin of mice deficient in myeloperoxidase and NADPH oxidase , 2006, Inflammation Research.

[17]  S. Klebanoff.  Myeloperoxidase: friend and foe , 2005, Journal of leukocyte biology.

[18]  A. Karlsson,et al.  Respiratory burst in human neutrophils. , 1999, Journal of immunological methods.

[19]  D. Niethammer,et al.  Phagocytic Activity and Oxidative Burst of Granulocytes in Persons with Myeloperoxidase Deficiency , 1996, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[20]  R. Weissleder,et al.  Imaging reactive oxygen species in arthritis. , 2004, Molecular imaging.

[21]  C. Dahlgren,et al.  Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of superoxide anion from human neutrophils. , 1996, Free radical biology & medicine.

[22]  D. Bass,et al.  Mechanism of the luminol-dependent chemiluminescence of human neutrophils. , 1982, Journal of immunology.

[23]  R. Allen,et al.  Phagocytic activation of a luminol-dependent chemiluminescence in rabbit alveolar and peritoneal macrophages. , 1976, Biochemical and biophysical research communications.

[24]  Hendrik Streeck,et al.  The role of IFN-γ Elispot assay in HIV vaccine research , 2009, Nature Protocols.

[25]  J. Crowley,et al.  Increased atherosclerosis in myeloperoxidase-deficient mice. , 2001, The Journal of clinical investigation.

[26]  D. Douer,et al.  An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. , 1997, Blood.

[27]  H. Matthews,et al.  Metabolism and disposition of luminol in the rat , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[28]  R. Weissleder,et al.  Myeloperoxidase Activity Imaging Using 67Ga Labeled Substrate , 2005, Molecular Imaging and Biology.

[29]  P. Libby,et al.  Activatable Magnetic Resonance Imaging Agent Reports Myeloperoxidase Activity in Healing Infarcts and Noninvasively Detects the Antiinflammatory Effects of Atorvastatin on Ischemia-Reperfusion Injury , 2008, Circulation.

[30]  H. Birnboim,et al.  A myeloperoxidase-specific assay based upon bromide-dependent chemiluminescence of luminol. , 1999, Analytical biochemistry.

[31]  E. Topol,et al.  Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.

[32]  S. Paulson,et al.  Dermal inflammation in primates, mice, and guinea pigs: Attenuation by second-generation leukotriene B4 receptor antagonist, SC-53228 , 1995, Inflammation.

[33]  J. Mahoney,et al.  Thiocyanate is the major substrate for eosinophil peroxidase in physiologic fluids. Implications for cytotoxicity. , 1991, The Journal of biological chemistry.

[34]  M. Bednar,et al.  Peroxynitrite augments fMLP‐stimulated chemiluminescence by neutrophils in human whole blood , 1996, Journal of leukocyte biology.

[35]  M. Hallett,et al.  Detection and visualization of oxidase activity in phagocytes. , 2003, Methods in molecular biology.

[36]  C. Gedye,et al.  Inhibition of myeloperoxidase by benzoic acid hydrazides. , 1995, The Biochemical journal.

[37]  R. Crystal,et al.  Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. , 1987, The Journal of clinical investigation.

[38]  T. Ley,et al.  Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Epps,et al.  Altered function of synovial fluid granulocytes in patients with acute inflammatory arthritis , 1986, Inflammation.

[40]  M. Tharp,et al.  Contact hypersensitivity reactions to dinitrofluorobenzene mediated by monoclonal IgE anti-DNP antibodies. , 1983, Journal of immunology.

[41]  P. Libby,et al.  A novel fluorescent probe for the detection of myeloperoxidase activity in atherosclerosis-associated macrophages , 2009 .

[42]  L. Račková,et al.  The combined luminol/isoluminol chemiluminescence method for differentiating between extracellular and intracellular oxidant production by neutrophils , 2006, Redox report : communications in free radical research.

[43]  T. Müller,et al.  Luminol-dependent chemiluminescence in bovine eosinophils and neutrophils: differential increase of intracellular and extracellular chemiluminescence induced by soluble stimulants. , 1991, Journal of bioluminescence and chemiluminescence.